| 1 |
Effects of an SGLT2 inhibitor on salt sensitivity of blood pressure and sympathetic nerve activity in a non-diabetic rat model of chronic kidney disease.
Wan N, Rahman A, Nishiyama A.
(Virtual)International Society of Hypertension. Glasgow. Apr. 2021. |
| 2 |
Antiproliferative effects of monoclonal antibodies against (pro)renin receptor in pancreatic ductal adenocarcinoma.
Nishiyama A, Matsuyama M, Ebihara A, Shibayama Y, Rahman A.
(Virtual)International Society of Hypertension. Glasgow. Apr. 2021. |
| 3 |
Failure to confirm a SGLT2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Yamazaki D, Konishi Y, Morikawa T, Nishiyama A.
(Virtual)International Society of Hypertension. Glasgow. Apr. 2021. |
| 4 |
Mineralocorticoid receptor (MR) antagonist.
Nishiyama A.
(Virtual)Asian Pacific Congress of Nephrology. Bangkok. Aug. 2021.
|
| 5 |
Pathophysiological mechanism of mineralocorticoid receptor-dependent chronic kidney disease.
Nishiyama A.
(Virtual)The 19th International Symposium on Atherosclerosis. Kyoto. Oct. 2021. |
| 6 |
Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
Katagiri N, Hitomi H, Mae S, Kotaka M, Lei L, Yamamoto T, Nishiyama A, Osafune K.
(Virtual)The International Society for Stem Cell Research. Tokyo. Oct. 2021. |
| 7 |
New Concept of Onco-Hypertension and Future Perspectives.
Nishiyama A.
(Virtual)55th Scientific Meeting of the Korean Society of Hypertension. Seoul. Nov. 2021. |